ICON Acquires BeijingWits Medical Consulting Ltd
12 Dezembro 2011 - 8:00AM
Business Wire
ICON plc, (NASDAQ: ICLR; ISIN: IE0005711209), a global
provider of outsourced development services to the pharmaceutical,
biotechnology and medical device industries, today announced that
it has agreed, subject to closing conditions, to acquire
BeijingWits Medical Consulting Ltd., a leading CRO in China. The
transaction is expected to close in the first quarter of 2012.
BeijingWits offers full-service clinical development
capabilities and has a strong track record in clinical trial
execution in China. The company is a renowned expert in Chinese
regulatory processes and a leading advocate of ICH GCP in China. In
addition to boosting ICON’s service capabilities in the region,
BeijingWits will also strengthen ICON’s presence through the
addition of over 100 highly qualified and experienced professionals
in Beijing, Shanghai, Chengdu, Guangzhou, Wuhan and Hong Kong.
“The acquisition of BeijingWits is a further step in our
on-going expansion in China and the greater Asia-Pacific region,”
commented Ciaran Murray, CEO, ICON plc. “An increasing number of
our global clients are looking to undertake research in China and
local companies are also placing more emphasis on R&D, which
has resulted in growing demand for local clinical trial expertise.
BeijingWits brings to ICON a strong leadership team, experienced
staff and good relationships with local investigator sites and
regulatory bodies.”
“We are delighted to be joining with ICON,” commented Dr. Yan
Bin Xie, General Manager and founder of BeijingWits Medical
Consulting Company. “The clinical research market in China is at an
exciting stage and combining our local knowledge with ICON’s global
infrastructure and experience will offer clients a formula for
successful clinical development. ICON has strong growth plans for
China and Asia-Pacific and we look forward to playing a leading
role in helping them achieve these goals.”
About Beijing Wits Medical Consulting Company
Beijing Wits Medical Consulting Company was founded in 1997. The
company provides services to global and local pharmaceutical,
medical device and biotechnology companies focusing on Phase I to
IV Clinical studies. Beijing Wits currently has more than 100
employees, operating from 6 offices in China.
About ICON plc
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries.
The Company specialises in the strategic development, management
and analysis of programs that support clinical development - from
compound selection to Phase I-IV clinical studies. ICON currently
has approximately 8,300 employees, operating from 77 locations in
39 countries.
Further information is available at www.iconplc.com
Cautionary Note Regarding Forward-Looking Statements
This release contains, and our officers and representatives may
from time to time make, "forward-looking statements" within the
meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "expect," "strategy" and similar references to
future periods. Examples of forward-looking statements include,
among others, statements we make regarding our expectations that
the transaction will close and the timing of the closing, including
our belief that the conditions to closing will be satisfied; and
our belief that, upon completion of the transaction, BeijingWits
will strengthen our presence and will allow us to further our
growth plans in China. Forward-looking statements are neither
historical facts nor assurances of future performance. Instead,
they are based only on our current beliefs, expectations and
assumptions regarding the future of our business, future plans and
strategies, anticipated events and trends, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results may differ
materially from those indicated in the forward-looking statements.
Therefore, you should not rely on any of these forward-looking
statements. Important factors that could cause our actual results
to differ materially from those indicated in the forward-looking
statements include, among others, the risk that the conditions to
closing the transaction are not satisfied and, therefore, that the
transaction does not close on a timely basis, or at all; strategic
actions, including our success in integrating BeijingWits; general
economic and financial conditions; the extent to which we are
successful in implementing our strategy, gaining new, long-term
relationships with customers and retaining existing ones; the risk
of competition on our industry; developments and changes in laws
and regulations; and such other factors as discussed in Part I,
Item 3 “Risk Factors” in our Form 20-F for the fiscal year ended
December 31, 2010. Any forward-looking statement made by us in this
release is based only on information currently available to us and
speaks only as of the date on which it is made. We undertake no
obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
ICON/ICLR-G
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024